Clinical trials: Thoracic Tumor
Solid Tumor, Small Cell and Non-small Cell Lung Cancer
RAPA-201 Therapy of Solid Tumors
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of…
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT05144698
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rapa Therapeutics LLC
Lung Cancer
Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers
This research study involves taking an experimental anti-cancer dietary supplement called Sulforaphane (SF) or a placebo (product without any supplement content) over a period of twelve months in order to determine if it is a…
- Trial name
- NCT03232138
- Testing
- Sulforaphane
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Jian-Min Yuan, MD
Non-small Cell Lung Cancer
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
- Trial name
- NCT04951648
- Testing
- Almonertinib, chemotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer, Metastatic Lung Carcinoma
Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II)
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and accounts for approximately 80% of all lung cancer cases.
- Trial name
- NCT07500285
- Testing
- Yttrium-90-Labeled Fibroblast Activation Protein Inhibitor (Y-90 FAPI)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 10 people
- Sponsor
- Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Lung Cancer, Surgery
VATS VS. Open Thoracic Surgery for Stage II - III Lung Cancer
For patients with stage I lung cancer, the NCCN guidelines point out that if the patient has no contraindications for anatomy and surgery, as long as it does not violate the standard of tumor treatment and the principle of…
- Trial name
- VOLCANO (NCT04009915)
- Testing
- VATS, Open surgery
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer Patients
Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients
We wants to analyse the EML4-ALK mutation rate in the patients who have non-small cell lung cancer.
- Trial name
- NCT01257308
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
Lung Cancer, Non-Small Cell
NSCLC Burden of Illness Study
The aim of this observational study is to identify and quantify the humanistic and economic burden of illness of patients with complete resection (no residual disease) of stage IB-IIIA NSCLC in three European countries (France…
- Trial name
- LuCaBIS (NCT01772225)
- Testing
- Data collection
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose [RP2CD]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents…
- Trial name
- KaRAnaSa (NCT07227025)
- Testing
- Amivantamab, Olomorasib
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Head and Neck Cancer, Lung Cancer
Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer
This is an multicenter study for preventive and therapeutic strategies for patients with head and neck cancer
- Trial name
- ALTAK (NCT01647425)
- Testing
- physician assessment
- Where
- 3 sites in France
- Volunteers
- 385 people
- Sponsor
- Centre Oscar Lambret
Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
- Trial name
- NAUTIKA1 (NCT04302025)
- Testing
- Alectinib, Entrectinib, Vemurafenib
- Where
- 38 sites in United States
- Volunteers
- 99 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer
FDG PET/CT Radiomics Analyses of Lung Cancer Patients Treated With Immunotherapy
The investigators propose iRADIOMICS, a highly innovative and potentially clinical practice changing tool, which will allow for better management of patients undergoing immunotherapy.
- Trial name
- NCT04007068
- Testing
- FDG PET/CT
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana
Non-Small-Cell Lung Cancer
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without famitinib in patients with advanced or metastatic NSCLC
- Trial name
- NCT04699968
- Testing
- SHR-1701，Famitinib, SHR-1701
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Thymoma and Thymic Carcinoma
Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor
This phase II study was to assess the efficacy and toxicity of hypofractionated radiotherapy (HRT) combined with weekly docetaxel/platinum and thymosin α1 in patients with unresectable or recurrent thymic epithelia tumors (TETs).
- Trial name
- NCT03663764
- Testing
- Thymosin a1, hypofractionated radiotherapy, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer
The development of stereotactic body radiation therapy (SBRT) for the treatment of stage I non-small cell lung cancer (NSCLC) has inspired a close partnership between thoracic surgery and radiation oncology.
- Trial name
- SORT (NCT05183932)
- Where
- 8 sites in United States, Canada
- Volunteers
- 446 people
- Sponsor
- Washington University School of Medicine
Malignant Thoracic Neoplasm
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
This clinical trial evaluates earlier symptom management through remote electronic symptom monitoring (such as through an app on patient's phone), and accessibility of palliative care self-referral by patients with thoracic…
- Trial name
- NCT06396598
- Testing
- Educational Activity, Electronic Health Record Review, Internet-Based Intervention
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Unresectable Advanced Solid Tumors, Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors
- Trial name
- NCT05527821
- Testing
- Surufatinib, Sintilimab, Short course radiotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Adenocarcinoma of the Lung
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed…
- Trial name
- NCT01218516
- Testing
- Farletuzumab, Carboplatin, Paclitaxel
- Where
- 93 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Morphotek
Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
This is a Phase II clinical trial evaluating the efficacy and safety of a new treatment approach for patients with locally advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes on the opposite side of the…
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
- Trial name
- SACTION 2501 (NCT07309952)
- Testing
- Sintilimab, Paclitaxel, Carboplatin (AUC 5)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Yang Hong
NSCLC
SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases
Vertebral metastases are events that affect the quality of life of tumor patients, and are often accompanied by severe pain at the site of metastasis and even by the risk of compression fracture.
- Trial name
- NCT05577052
- Testing
- Metastatic vertebrae treated with SBRT
- Volunteers
- 100 people
- Sponsor
- Wuhan University
Relapsed Small Cell Lung Cancer
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with CS1001 in relapsed SCLC patients
- Trial name
- NCT04421352
- Testing
- CS1001
- Where
- China
- Volunteers
- 11 people
- Sponsor
- CStone Pharmaceuticals